Comparable stake leader
Kristen Fortney
SEC ownership of BioAge Labs, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001709941.
Disclosed value leader
a16z Capital Management, L.L.C.
Comparable rows
50/50
Latest evidence
15 May 2026
- Public ticker
- BIOA on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Kristen Fortney
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Kristen Fortney
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
15 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001709941
- Issuer location
- Emeryville, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BioAge Labs, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Kristen Fortney
Disclosed value leader
a16z Capital Management, ...
Comparable rows
50/50
Latest evidence
15 May 2026
13D/G
3/4/5
13F
Lead comparable stake: 7.2%
13D/G row: Kristen Fortney
Showing 1-8 of 50 holder rows.
Quick read
Kristen Fortney leads the comparable SEC ownership view at 7.2%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Kristen Fortney's linked filing trail.
Comparable ownership
Top 5
Kristen Fortney
7.2%
Cormorant Asset Management, LP
6.5%
BlackRock, Inc.
5%
Khosla Ventures VI, L.P.
4%
RA CAPITAL MANAGEMENT, L.P.
3.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Kristen Fortney |
13D/G
3/4/5
Chief Executive Officer, Director
|
7.2%
|
$48,279,538
2,704,736 shares
|
$0 | 31 Dec 2025 |
| Cormorant Asset Management, LP |
13F
13D/G
3/4/5
Company · Former 10% Owner
|
6.5%
from 13D/G
|
$50,556,681
2,890,605 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5%
from 13D/G
|
$39,663,052
2,267,756 shares
|
— | 31 Mar 2026 |
| Khosla Ventures VI, L.P. |
13D/G
VK Services, LLC
|
4%
|
$29,120,985
1,798,702 shares
|
$0 | 15 May 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
3.7%
from 13D/G
|
$28,869,834
1,650,648 shares
|
— | 31 Mar 2026 |
| ADAR1 Capital Management, LLC |
13D/G
13F
Company
|
0.4%
|
$2,419,746
135,560 shares
|
-$32,157,900 | 31 Dec 2025 |
| a16z Capital Management, L.L.C. |
13F
Company
|
7.2%
|
$56,548,143
3,233,170 shares
|
— | 31 Mar 2026 |
| Sofinnova Investments, Inc. |
13F
Company
|
5.1%
|
$40,118,352
2,293,788 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$7,792,358.
Buys
$0
Insiders: 0
Sells
$7,792,358
Insiders: 4
Net
-$7,792,358
Shares: -440,689
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 440,689
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 62,566 | $0 | $1,576,752 | -$1,576,752 |
| 3-6 | 0 | 16,253 | $0 | $307,974 | -$307,974 |
| 6-9 | 0 | 361,870 | $0 | $5,907,632 | -$5,907,632 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to BioAge Labs, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Vijay Satyanand Pande
Net 12M change
-$7,792,358
Latest report
29 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Vijay Satyanand Pande | Director | $58,197,060 | Mixed | 10 Jun 2026 | ||
| James Healy | Director | $41,488,218 | Filing P/S | 10 Jun 2026 | ||
| Patrick G. Enright | Director | $30,790,602 | Filing P/S | 10 Jun 2026 | ||
| Cormorant Asset Management, LP | Former 10% Owner | $29,331,522 | Filing P/S | 27 Sep 2024 | ||
| Kristen Fortney | Chief Executive Officer, Director | $17,698,701 | -$4,223,036 | -19% | Filing P/S | 17 Feb 2026 |
| Dov A. Goldstein MD | Chief Financial Officer | $639,718 | -$531,828 | -45% | Mixed | 23 Apr 2026 |
| Rekha Hemrajani | Director | $54,000 | Filing P/S | 10 Jun 2026 | ||
| Paul D. Rubin | Chief Medical Officer | $0 | -$1,460,742 | -100% | Mixed | 01 Apr 2026 |
| Shane Barton | Principal Accounting Officer | $0 | -$1,576,752 | -100% | Mixed | 29 Jun 2026 |
| Michael H. Davidson | Director | Mixed | 10 Jun 2026 | |||
| Jean Pierre Garnier | Director | Mixed | 10 Jun 2026 | |||
| Eric Morgen | Chief Operating Officer, Director | Mixed | 17 Feb 2026 |
Recent insider transactions for BioAge Labs, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Shane Barton | BIOA | Common Stock | Sale | -100% | $509,176 | $25.19 | -20,216 | 0 | 30 Jun 2026 | Direct |
| Shane Barton | BIOA | Common Stock | Options Exercise | 20,216 | 20,216 | 30 Jun 2026 | Direct | |||
| Shane Barton | BIOA | Stock Option (Right to Buy) | Options Exercise | -60.3% | -20,216 | 13,299 | 30 Jun 2026 | Direct | ||
| Shane Barton | BIOA | Common Stock | Sale | -100% | $1,067,576 | $25.21 | -42,350 | 0 | 29 Jun 2026 | Direct |
| Shane Barton | BIOA | Common Stock | Options Exercise | 1509% | 39,718 | 42,350 | 29 Jun 2026 | Direct | ||
| Shane Barton | BIOA | Stock Option (Right to Buy) | Options Exercise | -69.3% | -39,718 | 17,589 | 29 Jun 2026 | Direct | ||
| Vijay Satyanand Pande | BIOA | Stock Option (Right to Buy) | Award | 22,000 | 22,000 | 10 Jun 2026 | Direct | |||
| Rekha Hemrajani | BIOA | Stock Option (Right to Buy) | Award | 22,000 | 22,000 | 10 Jun 2026 | Direct | |||
| James Healy | BIOA | Stock Option (Right to Buy) | Award | 22,000 | 22,000 | 10 Jun 2026 | Direct | |||
| Patrick G. Enright | BIOA | Stock Option (Right to Buy) | Award | 22,000 | 22,000 | 10 Jun 2026 | Direct | |||
| Michael H. Davidson | BIOA | Stock Option (Right to Buy) | Award | 22,000 | 22,000 | 10 Jun 2026 | Direct | |||
| Jean Pierre Garnier | BIOA | Stock Option (Right to Buy) | Award | 22,000 | 22,000 | 10 Jun 2026 | Direct | |||
| Dov A. Goldstein MD | BIOA | Common Stock | Options Exercise | 10.7% | 3,542 | 36,575 | 23 Apr 2026 | Direct | ||
| Dov A. Goldstein MD | BIOA | Stock Option (Right to Buy) | Options Exercise | -2.22% | -3,542 | 155,833 | 23 Apr 2026 | Direct | ||
| Paul D. Rubin | BIOA | Common Stock | Sale | -100% | $157,084 | $17.81 | -8,820 | 0 | 01 Apr 2026 | Direct |
| Paul D. Rubin | BIOA | Common Stock | Options Exercise | 8,820 | 8,820 | 01 Apr 2026 | Direct | |||
| Paul D. Rubin | BIOA | Stock Option (Right to Buy) | Options Exercise | -100% | -8,820 | 0 | 01 Apr 2026 | Direct | ||
| Paul D. Rubin | BIOA | Common Stock | Sale | -100% | $150,890 | $20.30 | -7,433 | 0 | 02 Mar 2026 | Direct |
| Paul D. Rubin | BIOA | Common Stock | Options Exercise | 7,433 | 7,433 | 02 Mar 2026 | Direct | |||
| Paul D. Rubin | BIOA | Stock Option (Right to Buy) | Options Exercise | -68.7% | -7,433 | 3,383 | 02 Mar 2026 | Direct | ||
| Dov A. Goldstein MD | BIOA | Common Stock | Options Exercise | 12% | 3,542 | 33,033 | 01 Mar 2026 | Direct | ||
| Dov A. Goldstein MD | BIOA | Stock Option (Right to Buy) | Options Exercise | -2.17% | -3,542 | 159,375 | 01 Mar 2026 | Direct | ||
| Paul D. Rubin | BIOA | Stock Option (Right to Buy) | Award | 110,000 | 110,000 | 17 Feb 2026 | Direct | |||
| Eric Morgen | BIOA | Stock Option (Right to Buy) | Award | 12,500 | 12,500 | 17 Feb 2026 | By Spouse | |||
| Eric Morgen | BIOA | Stock Option (Right to Buy) | Award | 110,000 | 110,000 | 17 Feb 2026 | Direct | |||
| Dov A. Goldstein MD | BIOA | Stock Option (Right to Buy) | Award | 110,000 | 110,000 | 17 Feb 2026 | Direct | |||
| Kristen Fortney | BIOA | Stock Option (Right to Buy) | Award | 330,000 | 330,000 | 17 Feb 2026 | Direct | |||
| Shane Barton | BIOA | Stock Option (Right to Buy) | Award | 45,000 | 45,000 | 17 Feb 2026 | Direct | |||
| Paul D. Rubin | BIOA | Common Stock | Sale | -100% | $139,369 | $18.75 | -7,433 | 0 | 02 Feb 2026 | Direct |
| Paul D. Rubin | BIOA | Common Stock | Options Exercise | 7,433 | 7,433 | 02 Feb 2026 | Direct | |||
| Paul D. Rubin | BIOA | Stock Option (Right to Buy) | Options Exercise | -58% | -7,433 | 5,383 | 02 Feb 2026 | Direct | ||
| Dov A. Goldstein MD | BIOA | Common Stock | Options Exercise | 13.6% | 3,541 | 29,491 | 01 Feb 2026 | Direct | ||
| Dov A. Goldstein MD | BIOA | Stock Option (Right to Buy) | Options Exercise | -2.13% | -3,541 | 162,917 | 01 Feb 2026 | Direct | ||
| Dov A. Goldstein MD | BIOA | Common Stock | Options Exercise | 15.8% | 3,542 | 25,950 | 16 Jan 2026 | Direct | ||
| Dov A. Goldstein MD | BIOA | Stock Option (Right to Buy) | Options Exercise | -2.08% | -3,542 | 166,458 | 16 Jan 2026 | Direct | ||
| Dov A. Goldstein MD | BIOA | Common Stock | Sale | -54.6% | $531,828 | $19.70 | -27,000 | 22,408 | 13 Jan 2026 | Direct |
| Dov A. Goldstein MD | BIOA | Common Stock | Options Exercise | 120.5% | 27,000 | 49,408 | 13 Jan 2026 | Direct | ||
| Dov A. Goldstein MD | BIOA | Stock Option (Right to Buy) | Options Exercise | -22.6% | -27,000 | 92,587 | 13 Jan 2026 | Direct | ||
| Kristen Fortney | BIOA | Common Stock | Sale | -19.3% | $4,223,036 | $18.12 | -233,107 | 976,949 | 13 Jan 2026 | Direct |
| Paul D. Rubin | BIOA | Common Stock | Sale | -100% | $95,490 | $12.85 | -7,433 | 0 | 02 Jan 2026 | Direct |
| Paul D. Rubin | BIOA | Common Stock | Options Exercise | 7,433 | 7,433 | 02 Jan 2026 | Direct | |||
| Paul D. Rubin | BIOA | Stock Option (Right to Buy) | Options Exercise | -50.2% | -7,433 | 7,383 | 02 Jan 2026 | Direct | ||
| Paul D. Rubin | BIOA | Common Stock | Sale | -100% | $216,000 | $12.00 | -18,000 | 0 | 09 Dec 2025 | Direct |
| Paul D. Rubin | BIOA | Common Stock | Options Exercise | 18,000 | 18,000 | 09 Dec 2025 | Direct | |||
| Paul D. Rubin | BIOA | Stock Option (Right to Buy) | Options Exercise | -65.7% | -18,000 | 9,383 | 09 Dec 2025 | Direct | ||
| Paul D. Rubin | BIOA | Common Stock | Sale | -100% | $701,909 | $10.19 | -68,897 | 0 | 04 Dec 2025 | Direct |
| Paul D. Rubin | BIOA | Common Stock | Options Exercise | 68,897 | 68,897 | 04 Dec 2025 | Direct | |||
| Paul D. Rubin | BIOA | Stock Option (Right to Buy) | Options Exercise | -76% | -68,897 | 21,736 | 04 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.